Celularity's Biovance, Biovance 3L To Remain Eligible For Med. Coverage Under Withdrawn LCDs

CMS announced withdrawal of Local Coverage Determinations for skin substitutes (withdrawn Dec. 24, 2025; effective Jan. 1, 2026) but established a flat Medicare payment of $127.28 per square centimetre for skin substitute applications in physician offices and hospital outpatient settings. Celularity's Biovance and Biovance 3L remain eligible for Medicare coverage and CEO Robert Hariri stated the company can operate sustainably under the new payment model, highlighting its GMP/GTP New Jersey manufacturing facility and Industry 5.0, AI-enabled production systems. CELU traded in a $1.00–$4.35 range over the year and closed Friday at $1.34, up 1.52%.

Analysis

Market structure: CMS’s withdrawal of LCDs but imposition of a flat $127.28/cm2 reimbursement crystallises a lower, uniform price ceiling that favors low-cost, scale-capable producers and providers. Celularity (CELU) is a direct beneficiary because management states Biovance is sustainable at this rate and the company has an onshore GMP/GTP facility and digitised “Industry 5.0” throughput that lowers unit cost — this enhances CELU’s effective pricing power vs higher-cost peers and should shift share to efficient manufacturers over 12–24 months.

Risk assessment: Tail risks include a CMS reversal, private payer non-alignment, or legal challenges that cut reimbursement below $127.28 (high-impact, low-probability) and operational failures at Celularity’s NJ plant. Near-term (days–weeks) volatility will be driven by sentiment; medium-term (3–12 months) risks center on realized gross margins and adoption rates; long-term (12–36 months) risk is secular pricing compression and entrant competition leveraging cheaper biologics.

Trade implications: Direct actionable trade is a measured long in CELU sized 2–3% of portfolio with asymmetric optionality via a 9–12 month call spread (buy $2.50 / sell $5.00) — targets: double if Biovance commercial uptake yields quarterly Medicare billings >$3M within two quarters. Hedge with 50% notional 6‑month ATM puts to cap downside to ~30% and exit/trim if CELU falls 30% from entry or fails to report >$3M in Medicare billings by Q1 2026.

Contrarian angle: Consensus underestimates volume risk — flat pricing can reduce provider volume if alternative treatments become preferred, so the trade works only if Celularity converts share, not just coverage. Historical parallels (DME price resets) show winners are low cost-to-serve producers; if CELU’s onshore manufacturing fails to deliver <40% gross margin at $127.28/cm2, the upside is overstated and rapid de-risking is warranted.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in CELU equity within 7–30 days; set a hard stop-loss at 30% below entry and plan to take profits if share price doubles or if quarterly Medicare billings for Biovance exceed $3M within two reported quarters.
• Allocate 0.5–1.0% portfolio to a 9–12 month CELU call spread (buy $2.50 strike, sell $5.00 strike) to capture upside while limiting premium outlay; roll or close if CELU > $5.00 or if CMS materially changes policy.
• Purchase 50% notional 6‑month ATM puts against the CELU long to cap downside ~30% while preserving upside optionality; trim long by 50% if CELU misses the $3M quarterly Medicare billing threshold by Q1 2026 or trades below 70% of entry.
• Reduce 20–50% exposure to small-cap wound-care/skin-substitute equities with >30% revenue indexed to Medicare reimbursement over the next 2 weeks; reallocate proceeds to names with onshore manufacturing or diversified payer mix.